Protein tyrosine phosphatase PTPN22 +1858C/T polymorphism is associated with active vitiligo

Vitiligo is characterized by a skin depigmentation disorder resulting from an autoimmune response targeting melanocytes. Within the genetic factors involved in the development of the vitiligo immune response, various genes in the major histocompatibility complex (MHC) and non-MHC loci have been considered to be risk factors. The PTPN22 gene encodes for a lymphoid protein tyrosine phosphatase, a regulator of the activation and development of T-cells. The +1858C/T polymorphism has been associated to autoimmune disease susceptibility in different populations and could be implicated in the onset of vitiligo. To assess the possible association between the presence of PTPN22 +1858C/T and vitiligo, 187 patients with vitiligo and 223 control subjects were analyzed in the study. Genomic DNA was isolated using the salting-out method and samples were subjected to polymerase chain reaction-restriction fragment length polymorphism in order to detect the PTPN22 +1858C/T polymorphism. Causal associations were determined by χ2 test and their respective odds ratio (OR) was assessed in a 2×2 contingency table. The results showed an association between active vitiligo and the allele T load [P=0.0418; OR, 2.5706; 95% confidence interval (CI), 1.0040–6.5816], and active vitiligo-CT genotype (P=0.0389, OR, 2.6548; 95% CI, 1.0191–6.9156). In conclusion, the present data indicates a possible association between the PTPN22 +1858C/T genotype and a significant susceptibility of developing an active form of vitiligo.

[1]  J. Lambert,et al.  Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  D. Parsad,et al.  Stability in Vitiligo: Is there a Perfect Way to Predict it? , 2013, Journal of cutaneous and aesthetic surgery.

[3]  Javier Martín,et al.  Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis , 2013, Molecular vision.

[4]  R. E. Abu Khalil,et al.  PTPN22 gene polymorphism in Egyptian females with non-segmental vitiligo , 2013, Comparative Clinical Pathology.

[5]  Y. Lee,et al.  The CTLA-4 +49A/G, CT60A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis , 2012, Molecular Biology Reports.

[6]  H. Rangel-Villalobos,et al.  The +1858C/T PTPN22 gene polymorphism confers genetic susceptibility to rheumatoid arthritis in Mexican population from the Western Mexico. , 2012, Immunology letters.

[7]  S. Amur,et al.  Sex differences and genomics in autoimmune diseases. , 2012, Journal of autoimmunity.

[8]  Jeffrey S. Chang,et al.  PTPN22 C1858T and the risk of psoriasis: a meta-analysis , 2012, Molecular Biology Reports.

[9]  Garth L Burn,et al.  Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? , 2011, FEBS letters.

[10]  R. Sánchez-Porras,et al.  Immunopathogenesis of vitiligo. , 2011, Autoimmunity reviews.

[11]  K. Siminovitch,et al.  The autoimmune disease–associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness , 2011, Nature Genetics.

[12]  Dariush Moussai,et al.  Th17 Cells and Activated Dendritic Cells Are Increased in Vitiligo Lesions , 2011, PloS one.

[13]  Yu. V. Kudryashova,et al.  Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population , 2011, Aging.

[14]  E. Dellambra,et al.  Vitiligo: pathogenetic hypotheses and targets for current therapies. , 2010, Current drug metabolism.

[15]  D. Grattapaglia,et al.  Allele and haplotype frequency distribution in PTPN22 gene across variable ethnic groups: Implications for genetic association studies for autoimmune diseases , 2010, Autoimmunity.

[16]  M. Aris Origen del melanocito normal y maligno , 2009 .

[17]  M. Hermiston,et al.  PTPN22 Deficiency Cooperates with the CD45 E613R Allele to Break Tolerance on a Non-Autoimmune Background1 , 2009, The Journal of Immunology.

[18]  A. Xu,et al.  Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo , 2009, International journal of dermatology.

[19]  M. Aris,et al.  Origin of normal and malignant melanocytes , 2009 .

[20]  R. Spritz,et al.  The PTPN22‐1858C>T (R620W) functional polymorphism is associated with generalized vitiligo in the Romanian population , 2008, Pigment cell & melanoma research.

[21]  V. Sehgal,et al.  Vitiligo: compendium of clinico-epidemiological features. , 2007, Indian journal of dermatology, venereology and leprology.

[22]  Sheri L. Riccardi,et al.  NALP1 in vitiligo-associated multiple autoimmune disease. , 2007, The New England journal of medicine.

[23]  N. Bottini,et al.  Protein tyrosine phosphatase PTPN22 in human autoimmunity , 2007, Autoimmunity.

[24]  D. Gawkrodger,et al.  Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. , 2007, Autoimmunity reviews.

[25]  R. Spritz The genetics of generalized vitiligo and associated autoimmune diseases. , 2007, Pigment cell research.

[26]  L. Orozco,et al.  Association analysis of the PTPN22 gene in childhood-onset systemic lupus erythematosus in Mexican population , 2006, Genes and Immunity.

[27]  C. Farrar,et al.  Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients. , 2006, Rheumatology.

[28]  R. Begum,et al.  Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. , 2006, Indian journal of experimental biology.

[29]  R. Schwartz,et al.  Vitiligo: a sign of systemic disease. , 2006, Indian journal of dermatology, venereology and leprology.

[30]  D. Gawkrodger,et al.  A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo , 2005, Genes and Immunity.

[31]  Xuejun Zhang,et al.  The genetic concept of vitiligo. , 2005, Journal of dermatological science.

[32]  J. Rodríguez-López,et al.  Vitíligo. Tratamiento de 12 casos con tacrolimus tópico , 2005 .

[33]  J. Rodríguez-López,et al.  [Vitiligo. Treatment of 12 cases with topical tacrolimus]. , 2005, Actas dermo-sifiliograficas.

[34]  Nunzio Bottini,et al.  A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes , 2004, Nature Genetics.

[35]  S. Dogra,et al.  Health and Quality of Life Outcomes , 2003 .

[36]  E. Shaoul,et al.  Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. , 1999, Blood.